Study:
Cisplatin, Irinotecan and Bevacizumab (NSC #704865, IND #7921) for Untreated Extensive Stage Small Cell Lung Cancer: A Phase II Study
Rationale:
Drugs used in chemotherapy, such as cisplatin and irinotecan, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the
growth of small cell lung cancer by blocking blood flow to the tumor. Giving cisplatin and
irinotecan together with bevacizumab may kill more tumor cells.
Purpose:
This phase II trial is studying how well giving cisplatin and irinotecan together
with bevacizumab works in treating patients with extensive-stage small cell lung cancer.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Lung Cancer |
Biological: bevacizumab
Drug: cisplatin
Drug: irinotecan hydrochloride |
Phase 2 |
Verified by
Cancer and Leukemia Group B
December, 2012
Sponsored by: Cancer and Leukemia Group B
Information provided by: Cancer and Leukemia Group B
ClinicalTrials.gov identifier: NCT00118235
Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Florida - Weston
Weston, Florida 33331
United States
Neal Ready, MD, PhD., Study Chair